Stocks To Watch, March 2: ONGC, OIL, OMCs, paints, and aviation, L&T, Maruti, Tata Motors, defence stocks, Brigade Enterprises

Leading automakers Maruti Suzuki, Tata Motors Passenger Vehicles, Mahindra & Mahindra, and Hyundai reported an increase in vehicle dispatches to dealers in February, riding on sustained demand in the domestic market.

Car market leader Maruti Suzuki India said its domestic passenger vehicle sales rose to 1,61,000 units last month against 1,60,791 units in February 2025.

Tata Motors Passenger Vehicles reported a 34 per cent rise in passenger vehicle dispatches at 62,329 units last month, as against 46,435 units in the year-ago period.

Mahindra & Mahindra said its utility vehicle sales in the domestic market last month increased 19 per cent to 60,018 units compared to 50,420 units in the year-ago period.

M&M CEO, Automotive Division, Nalinikanth Gollagunta, said the February performance reflected "robust customer demand across the portfolio".

Hyundai Motor India said its domestic sales grew 10 per cent year on year to 52,407 units in February.

The company's MD and CEO, Tarun Garg, said, "We kicked off 2026 on a high note, achieving our highest-ever monthly sales in January, and the momentum continues in February."

Following the arrest, a special board meeting was convened wherein Ketan Merchant, chief financial officer of the bank, was appointed as head of the organisation to carry on and oversee day-to-day operations, Fino Payments Bank said in a regulatory filing.

Gupta has been "arrested under the provisions of Sections 132(1)(a) and 132(1)(i) of the CGST and SGST Act, 2017", it said.

The investigation is related to business partner(s) of the bank, and not GST compliance by it, the bank said.

"By combining Airtel’s network intelligence with Google’s Rich Communications Services (RCS) platform and spam filtering, users get to experience RCS messaging with high-quality photo/video and interactive elements like message reactions, all while benefiting from enhanced protections that significantly reduce mobile spam and digital fraud," the company said in its press release.

The inspection concluded with four observations. We will respond to the US FDA within the stipulated timelines.

In another development, BSE has sought clarification from the company following a news report titled "Aurobindo Pharma's P. Sarath Chandra Reddy acquitted in Delhi Liquor Scam case".

The project is centrally located and seamlessly links Chennai’s Central Business District (CBD) and the rapid-growth IT Corridor of Old Mahabalipuram Road (OMR).

The subsidiary was incorporated in India to set up state-of-the-art, advanced heterogeneous packaging and 3D packaging OSAT (Outsourced Semiconductor Assembly and Testing).

The block fits into strategic backward integration for the company's aluminium business.

Ivermectin Tablets USP, 3 mg, are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans, specifically intestinal strongyloidiasis and onchocerciasis.

Ivermectin tablets will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad, and distributed by Viona Pharmaceuticals Inc. Ivermectin Tablets USP, 3 mg, had annual sales of USD 14.8 mn.

This partnership leverages Novo Nordisk’s scientific leadership in GLP-1s and Abbott’s strong distribution network to expand access in India to a high-quality, evidence-based diabetes therapy beyond regions Novo Nordisk currently serves.

Extensior® is a second brand of Ozempic®, the world’s most prescribed GLP-1 RA (receptor agonist) molecule.